ANI Pharmaceuticals Inc (ANIP)
65.21
-0.22
(-0.34%)
USD |
NASDAQ |
Apr 25, 12:57
ANI Pharmaceuticals Enterprise Value: 1.468B for April 24, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 24, 2024 | 1.468B |
| April 23, 2024 | 1.483B |
| April 22, 2024 | 1.472B |
| April 19, 2024 | 1.469B |
| April 18, 2024 | 1.450B |
| April 17, 2024 | 1.469B |
| April 16, 2024 | 1.471B |
| April 15, 2024 | 1.486B |
| April 12, 2024 | 1.498B |
| April 11, 2024 | 1.524B |
| April 10, 2024 | 1.500B |
| April 09, 2024 | 1.502B |
| April 08, 2024 | 1.513B |
| April 05, 2024 | 1.515B |
| April 04, 2024 | 1.521B |
| April 03, 2024 | 1.506B |
| April 02, 2024 | 1.495B |
| April 01, 2024 | 1.519B |
| March 28, 2024 | 1.546B |
| March 27, 2024 | 1.558B |
| March 26, 2024 | 1.555B |
| March 25, 2024 | 1.556B |
| March 22, 2024 | 1.555B |
| March 21, 2024 | 1.550B |
| March 20, 2024 | 1.525B |
| Date | Value |
|---|---|
| March 19, 2024 | 1.519B |
| March 18, 2024 | 1.514B |
| March 15, 2024 | 1.480B |
| March 14, 2024 | 1.481B |
| March 13, 2024 | 1.485B |
| March 12, 2024 | 1.491B |
| March 11, 2024 | 1.483B |
| March 08, 2024 | 1.510B |
| March 07, 2024 | 1.495B |
| March 06, 2024 | 1.476B |
| March 05, 2024 | 1.466B |
| March 04, 2024 | 1.489B |
| March 01, 2024 | 1.505B |
| February 29, 2024 | 1.515B |
| February 28, 2024 | 1.359B |
| February 27, 2024 | 1.352B |
| February 26, 2024 | 1.359B |
| February 23, 2024 | 1.335B |
| February 22, 2024 | 1.315B |
| February 21, 2024 | 1.269B |
| February 20, 2024 | 1.284B |
| February 16, 2024 | 1.312B |
| February 15, 2024 | 1.267B |
| February 14, 2024 | 1.238B |
| February 13, 2024 | 1.215B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
462.56M
Minimum
Nov 06 2020
1.558B
Maximum
Mar 27 2024
872.81M
Average
866.93M
Median
Jan 24 2020
Enterprise Value Benchmarks
| Ligand Pharmaceuticals Inc | 1.087B |
| ADMA Biologics Inc | 1.554B |
| Dentsply Sirona Inc | 8.197B |
| Allogene Therapeutics Inc | 65.34M |
| Vanda Pharmaceuticals Inc | -125.89M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 1.155M |
| Revenue (Quarterly) | 131.65M |
| Total Expenses (Quarterly) | 122.94M |
| EPS Diluted (Quarterly) | 0.02 |
| Gross Profit Margin (Quarterly) | 59.42% |
| Profit Margin (Quarterly) | 0.88% |
| Earnings Yield | 1.26% |
| Operating Earnings Yield | 4.17% |
| Normalized Earnings Yield | 1.404 |